Houzen Hideki, Kano Takahiro, Horiuchi Kazuhiro, Wakita Masahiro, Nagai Azusa, Yabe Ichiro
Department of Neurology, Obihiro Kosei Hospital, Obihiro 080-0024, Hokkaido, Japan.
Department of Neurology, Hakodate Municipal Hospital, Hakodate 041-8680, Hokkaido, Japan.
Pharmaceuticals (Basel). 2021 Jul 21;14(8):705. doi: 10.3390/ph14080705.
Reports on the long-term survival effect of edaravone, which was approved for the treatment of amyotrophic lateral sclerosis (ALS) in 2015 in Japan, are rare. Herein, we report our retrospective analysis of 45 consecutive patients with ALS who initially visited our hospital between 2013 and 2018. Of these, 22 patients were treated with edaravone for an average duration of 26.6 (range, 2-64) months, whereas the remaining patients were not treated with edaravone and comprised the control group. There were no differences in baseline demographics between the two groups. The primary endpoint was tracheostomy positive-pressure ventilation (TPPV) or death, and the follow-up period ended in December 2020. The survival rate was significantly better in the edaravone group than in the control group based on the Kaplan-Meier analysis, which revealed that the median survival durations were 49 (9-88) and 25 (8-41) months in the edaravone and control groups, respectively ( = 0.001, log-rank test). There were no serious edaravone-associated adverse effects during the study period. Overall, the findings of this single-center retrospective study suggest that edaravone might prolong survival in patients with ALS.
依达拉奉于2015年在日本被批准用于治疗肌萎缩侧索硬化症（ALS），关于其长期生存效果的报告很少。在此，我们报告了对2013年至2018年间首次到我院就诊的45例连续性ALS患者的回顾性分析。其中，22例患者接受了依达拉奉治疗，平均治疗时长为26.6（范围2 - 64）个月，其余患者未接受依达拉奉治疗，组成对照组。两组患者的基线人口统计学特征无差异。主要终点为气管切开正压通气（TPPV）或死亡，随访期至2020年12月结束。基于Kaplan - Meier分析，依达拉奉组的生存率显著优于对照组，结果显示依达拉奉组和对照组的中位生存时长分别为49（9 - 88）个月和25（8 - 41）个月（对数秩检验，P = 0.001）。研究期间未出现与依达拉奉相关的严重不良反应。总体而言，这项单中心回顾性研究的结果表明依达拉奉可能会延长ALS患者的生存期。
